Sakamakon ya nuna cewa wannan magani zai iya rage cutar Alzheimer
Ina son rubuta rubutun game da lalata da cutar Alzheimer . Cutar cutar Alzheimer wata cuta ce mai zafi. Yana ci gaba ba tare da bata lokaci ba. Dokokin FDA da aka yarda da su don magance wannan cuta kamar Aricept, Nemenda, da Cognex ba su yi jinkiri ba.
Yawancin masu bincike ba su san cewa magunguna suna da iyakaci ga marasa lafiya da cutar Alzheimer.
Duk da haka, ƙaunatattun suna buƙatar waɗannan magunguna tare da bege cewa waɗannan nau'ikan zasu iya taimakawa cikin ƙananan hanya. Daga karshe, mafi kyawun magani ga waɗanda ke da cutar Alzheimer shine kulawa mai tausayi wanda ba wai kawai ya adana kyakkyawar rayuwa ga mutumin da ke fama da cutar ba, har ma da kyautar rayuwa ga mai kulawa kanta.
Duk da rashin amincewar da na rubuta game da cutar Alzheimer, na amince da kaina don magance wannan cuta ne kawai idan wani gwajin magani na asibitocin ya nuna jinkirta rage karfin zuciya ga wadanda ke fama da cutar. Kwanan nan, sakamakon farko daga gwaji da suka shafi aducanumab na Biogen ya nuna cewa wannan ƙwayar cuta daya zai iya hana ci gaban cutar Alzheimer.
Cutar cutar Alzheimer ita ce mafi yawan al'ada. A {asar Amirka, kimanin miliyan 5 na Amirka da suka kai shekaru 65 da haihuwa sun kasance tare da cutar. Kwayar cuta na Alzheimer yana da jinkiri kuma ba shi da komai.
Yawancin lokaci, tunanin Alzheimer na ƙwaƙwalwa, tunani, da tunani. Daga ƙarshe, mutumin da ke fama da mummunan mummunar cutar ya bar ba zai iya yin ko da aikin da ya fi sauƙi ba kuma ayyukan rayuwar yau da kullum.
Sanarwarmu na yanzu game da cututtuka na cutar Alzheimer tana da iyaka ga "amyloid hypothesis ". Musamman, ƙin neurodegeneration zai iya samuwa da ajiyar adadin amyloid-beta (Aß) peptides a cikin kwakwalwa.
Haɗakar Aß ta kori Alzheimer ta cutar pathogenesis. Wani lamarin da ya ba da gudummawa ya ƙunshi neurofibrillary tangles hada da gina jiki mai gina jiki. Rashin daidaituwa tsakanin aikin Aß da kuma Aß ketare ya haifar da kafa wadannan matakan.
A yau, an yi amfani da kwayar cutar daban-daban don magance cutar Alzheimer ta hanyar amyloid. Musamman, antibody aducanumab yana aiki ne ta hanyar haifar da phagocytosis na Fc-receptor na alamun Aß. A wasu kalmomi, aducanumab yana ƙarfafa jikinmu na phagocytes don sarrafa Aß.
A cikin 'yan shekarun nan,' yan amyloid sunyi tambayoyi da yawa kuma sunyi amfani da su da yawa kamar yadda aka dauka. Har yanzu ba mu da tabbaci na asibiti don maganin, kuma mutane da yawa sun gaskata cewa tarawar Aß na iya zama ɓangare na tsari mai girma da rashin fahimta wanda ke haifar da neurodegeneration. Mafi mahimmanci, a cikin waɗanda ke da cutar Alzheimer, Sakamakon baya ya wuce karfin zuciya daga shekaru 10 zuwa 15 don haka ya haddasa shawarar da ya dace da dangantaka da tasiri. Bugu da ƙari kuma, ƙwayar amyloid precursor gina jiki (APP) ba wai kawai Aß ba har ma wasu ƙananan rassan da zasu iya taka muhimmiyar rawa a cikin tsarin maganin Alzheimer.
Bisa ga sakamakon lokaci na wani gwaji na gwaji na farko na 1b na aducanumab da ake kira PRIME, Biogen ya aikata zuwa gwaji na gwaji na 3 na magani.
Ga wasu daga cikin wadannan sakamakon lokaci:
- Jiyya tare da aducanumab ya haifar da rage yawan amyloid a cikin mutanen da ke fama da cutar Alzheimer ko rashin lafiya.
- Ragewa a cikin alamomi an duba ta ta amfani da hoton PET, kuma wannan raguwa ya kasance kashi- da kuma lokacin dogara.
- Bayan shekara guda na jiyya, mahalarta da cutar Alzheimer ta farko sun nuna rashin jin dadin jiki a cikin rashin fahimta kamar yadda jarrabawa ta M-Mental Status (MMSE) da Ƙwararrakin Ƙwararrakin Ƙware suka sha.
- Tsarin lafiya da haƙurin haƙuri na aducanumab ya yarda. Wasu cututtuka masu lalacewa sun hada da ciwon kai da kuma ARIA (amyloid related related abnormalities).
Domin maganin miyagun ƙwayoyi na Alzheimer ko wani sabon magani don yarda da FDA, dole ne ya wuce ta gwajin gwaji na 3 na gwaji. Kamar yadda aka tattauna a cikin wani labarin da aka ba da labarin "Gwajin gwagwarmayar gwagwarmaya ga b-secretase a Alzheimer" daga Biotechnology , wasu masu yin magungunan miyagun ƙwayoyi na Alzheimer sun fara zuwa gwaji na 3. Wannan aikin yana da haɗari saboda sakamakon rashin lafiya na asibiti daga gwajin gwaji na 3 yana rufe kwayar cutar. Bayan haka, babu wanda yake so ya zuba jari a cikin miyagun ƙwayoyi.
Abin da kawai saboda ƙwayar miyagun ƙwayoyi ba zai nuna sakamako mai mahimmanci a yayin da aka yi gwajin gwaji na farko na Phase 3 ba dole ba ne cewa magani ba ya aiki. Alal misali, yana yiwuwa mai magani zai iya zama tasiri a asoshin da ke gwada waɗanda aka gwada. Ko kuma, wasu kwayoyi suna aiki mafi kyau a kan wasu al'ummomi. Maimakon wucewa da Rubicon kuma ya yi gwajin gwaji na Phase 3, yana da kyakkyawan ra'ayin yin wani gwajin gwaji na Phase 2 kuma ya fahimci maganin miyagun ƙwayoyi da kuma tasirinsa. Sabanin haka, Biogen ya yanke shawarar ci gaba da gwaji na gwaji na 3 na aikin gwaji saboda karfafa ƙarfafawa daga sakamakon gwaji na (Phase 1b).
Idan kai ko ƙaunatacciyar shan wahala daga cutar Alzheimer, don Allah karanta wannan labarin a cikin mahallin kuma ba tare da fata ba. Biogene har yanzu ba da izinin tallafin aducanumab ba, kuma har yanzu muna buƙatar yalwacin sakamako masu asibiti. Ko da yake sakamakon farko game da aducanumab suna da alamar alkawari, kwayoyin Alzheimer sune sananne ne saboda rashin nasarar yanke mustard, kuma har yanzu ba mu gane wani maganin da ya dace ba don rage jinkirin wannan ciwon.
Sakamakon Zaɓuɓɓuka
Mataki mai suna "Harshen Amyloid na Cutar Alzheimer: Ci gaba da Alkawari a kan hanyoyin Harkokin Kiwon Lafiya" by J Hardy da DJ Selkoe da aka buga a Kimiyya a shekara ta 2002. An sami damar shiga ranar 3/22/2015.
Ropper AH, Samuels MA, Klein JP. Babi na 39. Cututtuka masu ƙwayoyin cuta na tsarin jiki. A: Ropper AH, Samuels MA, Klein JP. eds. Ka'idodin tsarin Adams da Victor na bita, 10th . New York, NY: McGraw-Hill; 2014. Samun dama ga Maris 22, 2015
Mataki na mai suna "Gwagwarmaya masu kariya ga masu cin zarafin ß-secretase a cikin Alzheimer ta Cormac Sheridan da aka buga a cikin yanayin Biotechnology a shekara ta 2015. An samu damar ranar 3/22/2015.